Sanofi is working with well-known moms to spread awareness about the importance of protecting infants from RSV using RSV in babies | For Parents This long-acting monoclonal antibody is the first approved option to prevent serious RSV-related lung infections in newborns and infants during their first RSV season. It also provides continued protection for children up to two years old who are still at risk during their second RSV season. BEYFORTUS is designed to protect all infants, including those born early or full-term, healthy or with health conditions, and it can be given at any time of the year.

Health Technology Insights: Brook.ai Boosts HEDIS Scores for Rural Healthcare Providers

RSV, or Respiratory Syncytial Virus, is the leading cause of hospitalizations in babies under one year old and a major cause of severe respiratory illnesses. To spread awareness, a group of influential moms are sharing their personal stories about why they chose to immunize their children with BEYFORTUS. The group includes actress and singer Mandy Moore, writer and birthFUND founder Elaine Welteroth, chef and author Gaby Dalkin, space advocate Katya Echazarreta, and Olympic gymnast Shawn Johnson East. Each of them has their own experience with RSV and has taken preventative steps for their children.

Mandy Moore, a mother of three, looked back on her family’s past experiences with RSV. She shared that both of her sons got sick with RSV at the same time, and although they didn’t need to go to the hospital, it was still a tough time. When her daughter Louise was born in September, she consulted her pediatrician, Dr. Danny Bruckner, about how to avoid going through that again. Dr. Bruckner immediately recommended BEYFORTUS and encouraged her to bring the baby in as soon as it was available. Mandy said choosing BEYFORTUS gave her peace of mind and felt like the best way to add a layer of protection for her daughter during RSV season.

Health Technology Insights: Livmor Launches AgentIQ: AI Medicare Platform for AEP

Dr. Daniel Bruckner, a board-certified pediatrician at Balboa Pediatrics, stressed how important RSV protection is for infants, especially during their first year. He explained that babies’ immune systems are still developing, making them more vulnerable to serious illness. In his practice, BEYFORTUS has become an important tool for keeping infants safe. He said many parents ask about RSV, and when they don’t, he brings it up himself because of how serious it can be. He recommends BEYFORTUS for all babies, whether they were born early or full-term, healthy or with existing medical issues.

Thomas Grenier, who leads Vaccines North America at Sanofi, talked about the growing impact BEYFORTUS is making in real-world situations. He noted that the treatment has been shown to be both safe and effective in clinical trials as well as in over 50 real-world studies including more than 400,000 infants. He added that millions of parents in the United States have already chosen BEYFORTUS to help protect their babies from RSV. According to Grenier, the moms sharing their stories are helping to spread the message that BEYFORTUS is not just an option, but currently the most prescribed choice for RSV prevention by pediatricians.

The website has helpful information about the treatment and why many families are choosing to protect their babies early. Sanofi encourages all parents to talk to their child’s doctor about how they can safely protect their infants from RSV using the most up-to-date options. Dr. Daniel Bruckner, Mandy Moore, Elaine Welteroth, Gaby Dalkin, Katya Echazarreta, and Shawn Johnson East are all paid spokespeople for Sanofi in support of this campaign.

Health Technology Insights: EQUASHIELD Unveils CellSHIELD for Cell and Gene Therapy

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com